SCALE Obesity and Prediabetes randomized 3,731 adults with overweight (plus comorbidity) or obesity, without diabetes, to liraglutide 3.0 mg daily or placebo over 56 weeks. Mean weight loss: 8.0% liraglutide vs 2.6% placebo; 63.2% lost ≥5% vs 27.1% placebo. Pivotal trial behind Saxenda's FDA approval (2014). First weight-loss GLP-1 to gain FDA approval. NEJM 2015.
Drugs in this category
Related terms
- Liraglutide
- First-generation GLP-1 receptor agonist; active ingredient in Saxenda and Victoza.